CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Bausch Health Companies Inc.

BHC
$2.00B
Mid Cap
NASDAQPharmaceutical PreparationsPharmaceuticals🇺🇸North AmericaQUEBEC7.0K employees

Bausch Health Companies Inc. (formerly Valeant and ICN Pharmaceuticals) is a global, diversified Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic pharmaceuticals, and over-the-counter products directly or indirectly in more than 90 countries and regions, including the United States, Canada, Europe, the Middle East, Africa, Asia Pacific and Latin America.

Website

Drugs in Pipeline

81

Phase 3 Programs

56

Upcoming Catalysts

2

Next Catalyst

Jul 29, 2026

5w

Market Overview

Stock performance and key metrics

BHC News
Catalyst Timeline

2 upcoming, 0 past

Drug Pipeline

Budesonide MMX®

Phase 3

Ulcerative Colitis

Viramidine

Phase 3

Chronic Hepatitis C

IDP 121 Lotion

Phase 3

Acne

NOV03

Phase 3

Dry Eye Disease

Budesonide MMX® 6 mg

Phase 3

Ulcerative Colitis

Tramadol HCl ER

Phase 3

Chronic Pain

Mapracorat

Phase 3

Cataract

Budesonide MMX 6 mg Tablet

Phase 3

Ulcerative Colitis

IDP-120 Gel

Phase 3

Acne Vulgaris

Besifloxacin

Phase 3

Bacterial Conjunctivitis

BOL-303259-X

Phase 3

Open-Angle Glaucoma

Neuromultivit

Phase 3

Vertebrogenic Radiculopathy L5, S1

IDP-122 Vehicle Lotion

Phase 3

Psoriasis

Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks

Phase 3

Chronic Hepatitis C

Crofelemer 125 mg

Phase 3

HIV Associated Diarrhea

budesonide-MMX® 6 mg

Phase 3

Ulcerative Colitis

IDP-120 Vehicle Gel

Phase 3

Acne Vulgaris

Budesonide

Phase 3

Proctitis

SC Methylnaltrexone

Phase 3

Terminal Illness

IDP-118 Vehicle Lotion

Phase 3

Plaque Psoriasis

Loteprednol etabonate

Phase 3

Inflammation

tramadol ER

Phase 3

Chronic Pain

tramadol HCl ER; celecoxib

Phase 3

Chronic Pain

Encapsulated Mesalamine Granules (eMG)

Phase 3

Ulcerative Colitis

MOA-728

Phase 3

Constipation

bromfenac ophthalmic solution

Phase 3

Cataract

IDP-126 Vehicle Gel

Phase 3

Acne Vulgaris

IDP-123 Vehicle Lotion

Phase 3

Acne Vulgaris

Granulated mesalamine

Phase 3

Ulcerative Colitis

Bepreve

Phase 3

Allergic Conjunctivitis

Methylnaltrexone (MOA-728)

Phase 3

Post Operative Bowel Dysfunction

Bisacodyl

Phase 3

Chronic Idiopathic Constipation

Ribavirin

Phase 3

Chronic Hepatitis C

IDP-121 Lotion

Phase 3

Acne

open-label rifaximin

Phase 3

Irritable Bowel Syndrome With Diarrhea

Plecanatide

Phase 3

Chronic Idiopathic Constipation

5 ASA, enemas, suppositories, corticosteroids

Phase 3

Ulcerative Colitis

ACYC

Phase 3

Acne

SC Methylnaltrexone (MNTX)

Phase 3

Terminal Illness

IDP-126 Gel

Phase 3

Acne Vulgaris

IDP-118 Lotion

Phase 3

Plaque Psoriasis

IDP-124 Lotion

Phase 3

Atopic Dermatitis

IDP-124 Vehicle Lotion

Phase 3

Atopic Dermatitis

Rifaximin (Xifaxan)

Phase 3

Clostridium Infections

Rifaximin

Phase 3

Irritable Bowel Syndrome

Bromfenac

Phase 3

Allergic Conjunctivitis

Methylnaltrexone

Phase 3

Constipation

Rifaximin SSD

Phase 3

Hepatic Encephalopathy

N-methylnaltrexone bromide (MOA-728)

Phase 3

Constipation

Omeprazole sodium bicarbonate immediate release PWD/FS

Phase 3

Upper Gastrointestinal Bleeding

crofelemer

Phase 3

Irritable Bowel Syndrome

IDP-123 Lotion

Phase 3

Acne Vulgaris

Vitrase

Phase 3

Vitreous Detachment

210 mg brodalumab

Phase 3

Psoriatic Arthritis

Balsalazide disodium

Phase 3

Inflammatory Bowel Disease

IDP-122 Lotion

Phase 3

Plaque Psoriasis

SP-333 1 mg

Phase 2

Constipation

Taribavirin

Phase 2

Chronic Hepatitis C

IDP-118 Vehicle Cream

Phase 2

Psoriasis

1.2% JNJ 10229570-AAA

Phase 2

Acne Vulgaris

IDP-126 Component A

Phase 2

Acne Vulgaris

40 mg Rifaximin SSD once daily

Phase 2

Overt Hepatic Encephalopathy

Mesalamine Granules 750 mg

Phase 2

Irritable Bowel Syndrome With Diarrhea

SP-304 0.3 mg

Phase 2

Chronic Idiopathic Constipation

SC MNTX

Phase 2

Bowel Dysfunction

pradefovir mesylate

Phase 2

Hepatitis B, Chronic

Low Dose Rifaximin ER

Phase 2

Sickle Cell Disease

Lifitegrast/Perfluorohexyloctane Fixed Dose Combination

Phase 2

Dry Eye Disease

Tazorac Cream

Phase 2

Psoriasis

Rifaximin SSD 40 mg IR tablet

Phase 2

Liver Cirrhosis

IV Methylnaltrexone

Phase 2

Healthy Volunteers

Retin-A Micro 0.04% facial acne treatment

Phase 2

Acne Vulgaris

ISV-403

Phase 2

Bacterial Conjunctivitis

IDP-118 Monad HP Lotion

Phase 2

Plaque Psoriasis

Low Dose MT-1303

Phase 2

Ulcerative Colitis

Retigabine

Phase 2

Postherpetic Neuralgia

Methylnaltrexone bromide

Phase 2

Opioid-induced Constipation

SAN-300 0.5 mg/kg QW

Phase 2

Rheumatoid Arthritis

IDP 120 Component A Gel

Phase 2

Acne Vulgaris

IV Methylnaltrexone (MNTX)

Phase 2

Postoperative Ileus

70 mg SC

Phase 2

Psoriasis

Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply